GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (OTCPK:NVIVQ) » Definitions » Current Ratio
中文

InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Current Ratio : 14.30 (As of Sep. 2023)


View and export this data going back to 2010. Start your Free Trial

What is InVivo Therapeutics Holdings Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. InVivo Therapeutics Holdings's current ratio for the quarter that ended in Sep. 2023 was 14.30.

InVivo Therapeutics Holdings has a current ratio of 14.30. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for InVivo Therapeutics Holdings's Current Ratio or its related term are showing as below:

NVIVQ' s Current Ratio Range Over the Past 10 Years
Min: 0.92   Med: 6.08   Max: 17.3
Current: 14.3

During the past 13 years, InVivo Therapeutics Holdings's highest Current Ratio was 17.30. The lowest was 0.92. And the median was 6.08.

NVIVQ's Current Ratio is ranked better than
88.61% of 1554 companies
in the Biotechnology industry
Industry Median: 3.795 vs NVIVQ: 14.30

InVivo Therapeutics Holdings Current Ratio Historical Data

The historical data trend for InVivo Therapeutics Holdings's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InVivo Therapeutics Holdings Current Ratio Chart

InVivo Therapeutics Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.77 2.55 9.97 7.33 7.13

InVivo Therapeutics Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.62 7.13 8.85 9.14 14.30

Competitive Comparison of InVivo Therapeutics Holdings's Current Ratio

For the Biotechnology subindustry, InVivo Therapeutics Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InVivo Therapeutics Holdings's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's Current Ratio distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's Current Ratio falls into.



InVivo Therapeutics Holdings Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

InVivo Therapeutics Holdings's Current Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Current Ratio (A: Dec. 2022 )=Total Current Assets (A: Dec. 2022 )/Total Current Liabilities (A: Dec. 2022 )
=17.601/2.468
=7.13

InVivo Therapeutics Holdings's Current Ratio for the quarter that ended in Sep. 2023 is calculated as

Current Ratio (Q: Sep. 2023 )=Total Current Assets (Q: Sep. 2023 )/Total Current Liabilities (Q: Sep. 2023 )
=9.525/0.666
=14.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InVivo Therapeutics Holdings  (OTCPK:NVIVQ) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


InVivo Therapeutics Holdings Current Ratio Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Business Description

Traded in Other Exchanges
Address
One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139
InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.
Executives
Brice Foose 10 percent owner 236 SILENT MEADOW DRIVE, LAKE ST. LOUIS MO 63367
Daniel R Marshak director C/O CAMBREX CORP, ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ 07073
Christina Morrison director ARAMARK, 1101 MARKET STREET, PHILADELPHIA PA 19107
Richard M. Toselli director, officer: CEO and CMO C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard Christopher officer: Chief Financial Officer C/O LUCID, INC., 50 METHODIST HILL DR, SUITE 1000, ROCHESTER NY 14623
C Ann Merrifield director
Bob Rosenthal director 20 NEWBURY ST, BOSTON MA 02116
Heather Hamel officer: Chief Legal Officer and GC ONE KENDALL SQUARE, BUILDING 1400 WEST, FLOOR 4, CAMBRIDGE MA 02139
Jeffrey Modestino officer: See Remarks C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14403, CAMBRIDGE MA 02139
Christopher Mcnulty officer: Chief Financial Officer C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Melanie Golarz officer: Interim CFO C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeffrey S. Hatfield director 11080 ROSELLE STREET, SAN DIEGO CA 92121
Pamela J Stahl officer: Chief Commercial Officer ONE KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard John Roberts director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Masuoka K. Lorianne officer: Chief Medical Officer C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070